| Degradation of CDK1 and HDACs as a strategy to treat T-cell malignancies |
|
|
|
Izr. prof. dr. Izidor Sosič |
|
CELSA |
|
1. 10. 2023 - 30. 9. 2025 |
Exploiting structural insights in IP3 receptor function to develop novel, allosteric
inhibitors of IP3 receptor channels (SINFONIC)
|
|
|
|
Prof. dr. Tihomir Tomašič
|
|
CELSA |
|
1. 10. 2023 - 30. 9. 2025 |
| A training network on the design of precision therapeutics that target key glycan motifs implicated in cancer |
|
GlyCanDrug |
|
Prof. dr. Marko Anderluh |
|
Horizon Europe |
|
1. 12. 2023 – 30. 11. 2027 |
| Protein degraders for targeting galectin-8 |
|
PROTAG-8 |
|
Prof. dr. Marko Anderluh |
|
Horizon Europe |
|
1. 9. 2024 – 31. 8. 2026 |
| The role of snoRNAs in the etiology of inflammatory bowel disease |
|
|
|
Izr. prof. dr. Tomaž Bratkovič |
|
CELSA |
|
1.10.2022 - 30.9.2024 |
| Razvoj raziskovalne infrastrukture za mednarodno konkurenčnost slovenskega RRI prostora |
|
|
|
Prof. dr. Irena Mlinarič-Raščan |
|
EATRIS ERIC |
|
2021 - 2030 |
| Digital Osce for Medical specialities - INnOvatlon for Students |
|
DOMINOS |
|
Prof. dr. Mitja Kos |
|
ERASMUS+ |
|
1.1.2022 - 31.12.2024 |
| EATRIS-Plus – flagship in personalized medicine |
|
EATRIS Plus |
|
Prof. dr. Irena Mlinarič-Raščan |
|
H2020 |
|
1.1.2020 - 31.12.2023 |
| REMEDI4ALL |
|
REMEDI4ALL |
|
Prof. dr. Irena Mlinarič-Raščan
Prof. dr. Rok Dreu |
|
Horizon Europe |
|
2021-2027 |
| European Partnership for the Assessment of Risks from Chemicals (PARC) |
|
PARC |
|
Prof. dr. Marija Sollner Dolenc |
|
Horizon Europe |
|
2022-2029 |
| Breaking the barrier - An integrated multidisciplinary approach to kill Gram-negative bacteria through existing antibiotics by making their outer membrane permeable |
|
BREAKthrough |
|
prof. dr. Stanislav Gobec |
|
Horizon Europe |
|
1. 1. 2023 – 31. 12. 2026 |